CYAD — Celyad Oncology SA Share News
0.000.00%
Last trade - 00:00- €9.93m
- €9.80m
- €0.02m
Belgium's Celyad H1 net loss narrows on lower expenses
Brief: Celyad Oncology Announces Research Facility Divestiture
Brief: Celyad H1 Net Income EUR -3.7 Million
Brief: Celyad Oncology Announces Potential Asset Sales, Restructuring, Mergers
Brief: Celyad Oncology Announces Intention To Terminate SEC Reporting Obligations
Brief: Celyad Oncology CEO Georges Rawadi Has Decided To Step Down, Effective December 1, 2023
Brief: Celyad Oncology End-Sept Cash, Cash Equivalents Of EUR 2.3 Million
Brief: Celyad Oncology Announces The Termination Of Its American Depository Receipt Program
Brief: Celyad Oncology SA Posts H1 Loss Per Share EUR 0.17
Brief: Celyad Oncology Receives About EUR 9.8 Million In Private Placement Commitments From Historical Shareholders
Brief: Celyad Oncology Announces Receipt Of Nasdaq Delisting Notice
Brief: Celyad Oncology Announces Receipt Of Nasdaq Delisting Notice
Brief: Celyad Oncology Announces Plan To Voluntarily Delist American Depository Shares From Nasdaq
Brief: Celyad Oncology Announces Receipt Of Nasdaq Initial Notification On ADS Bid Price
Brief: Celyad Oncology Announces Receipt Of Nasdaq Initial Notification On ADS Bid Price
Brief: Celyad Oncology Announces Receipt Of Nasdaq Notice
Brief: Celyad Oncology Appoints Georges Rawadi As Its New CEO
Brief: Celyad Oncology Reports Full Year 2022 Financial Results And Recent Business Highlights
Brief: Celyad Oncology End-December Treasury Position Of EUR 12.4 Mln